Anthropic adds Novartis CEO Vas Narasimhan to its board as it eyes IPO and leans into healthcare

Board move signals a new lane for the AI startup

Anthropic has appointed Novartis CEO Vas Narasimhan to its board, it has been reported that the move is the company’s second recent board addition as it prepares for an eventual IPO and pushes further into healthcare, according to the Wall Street Journal. Short and to the point: a leading pharma executive joining a high-profile AI lab looks like a handshake between two very different worlds. Why now? Timing matters — and so do optics.

What Narasimhan brings and why it matters

Narasimhan’s resume is heavy on global drug development, regulatory navigation and commercial scale-up, skills that matter when an AI company starts to talk about real-world health applications. It has been reported that his presence will bolster Anthropic’s credibility with healthcare partners, regulators and investors as the company explores clinical and commercial pathways for its models. This isn’t just an addendum to a board deck; it’s a signal that Anthropic wants to be taken seriously where human lives and data privacy intersect.

Bigger picture: governance, markets and the health sweep

The hire comes as AI firms increasingly court healthcare to show tangible impact and revenue paths — think of it as Big Tech meets Big Pharma. Adding industry heavyweights ahead of an IPO is textbook: shore up governance, reassure cautious investors, and add domain expertise. Stakes are high, though. Patient safety, regulatory scrutiny and ethical questions will follow; can Anthropic navigate that minefield while sprinting toward the public markets? The move raises hope, suspicion and a thousand follow-up questions.

Sources: wsj.com